EMA and the European medicines regulatory network are lifting their respective COVID-19 business continuity measures after successfully handling the unprecedented operational challenges posed by the pandemic. This was foreseen in

EMA’s workplan for 2023-2025

.

‘Throughout the pandemic we proved time and again that public health was our priority and ensured that patients in Europe could continue to have access to the newest, highest-quality therapeutics and vaccines,’ said Emer Cooke, EMA’s Executive Director. ‘Now that the peak of the pandemic has passed, the time is right for EMA and the network to close our business continuity measures. Our approach during the pandemic ensured that we could accelerate the assessment of therapeutics and vaccines for COVID-19 in an unprecedented manner while keeping assessment times for non-COVID products on schedule.’

EMA’s business continuity plan was introduced in 2020 to ring-fence resources to deal with…